Natural polyphenols in cancer therapy

Critical Reviews in Clinical Laboratory Sciences

Volumn 48, Issue 5-6, 2011, Pages 197-216

  Asensi, Miguel ^a,b   Ortega, Angel ^a,b   Mena, Salvador ^b   Feddi, Fatima ^b   Estrela, José M ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Green Molecular SL   (Spain)

Author keywords

cancer; curcumin; epigallocatechin 3 gallate; Polyphenols; quercetin; resveratrol

Indexed keywords

ACETIC ACID; APIGENIN; CATECHIN; CATECHIN 3 O GALLATE; CURCUMIN; CYANICLIN; DACARBAZINE; DAIDZEIN; ELLAGIC ACID; EPICATECHIN; EPICATECHIN 3 O GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; FOLINIC ACID; GENISTEIN; METHOXSALEN; OXALIPLATIN; POLYPHENOL DERIVATIVE; PROCYANIDIN; PSORALEN; PTEROSTILBENE; QUERCETIN; RESVERATROL; SECOISOLARICIRESINOL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENICITY; COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ESOPHAGUS CANCER; FOLLICULAR CARCINOMA; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; INTESTINE POLYP; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; OPEN ANGLE GLAUCOMA; OSTEOSARCOMA; OVARY CARCINOMA; PANCREAS CANCER; PLASMACYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ANIMALS; ANIMALS, LABORATORY; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; COLORECTAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MEDICINE, TRADITIONAL; MELANOMA; MOLECULAR STRUCTURE; NEOPLASMS; PLANT EXTRACTS; PLANTS, MEDICINAL; POLYPHENOLS; SKIN NEOPLASMS; TOXICITY TESTS;

EID: 84055197777     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2011.631268     Document Type: Review

References (246)

1. Dai J, Mumper RJ. Plant phenolics: Extraction, analysis and their antioxidant and anticancer properties. Molecules 2010;15:7313-7352.
2. Quideau S, Deffieux D, Douat-Casassus C, Pouységu L. Plant polyphenols: Chemical properties, biological activities, and synthesis. Angew Chem Int Ed Engl 2011;50:586-621.
3. Sies H. Polyphenols and health: Update and perspectives. Arch Biochem Biophys 2010;501:2-5.
4. Bravo L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998;56:317-333. (Pubitemid 28532456)
5. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr 2004;79:727-747. (Pubitemid 41103873)
6. Barry T, Forss D. The condensed tannin content of vegetative Lotus pedunculatus, its regulation by fertiliser application and effect upon protein solubility. J Sci Food Agric 1983;34:1047-1056.
7. Kampa M, Nifli AP, Notas G, Castanas E. Polyphenols and cancer cell growth. Rev Physiol Biochem Pharmacol 2007;159:79-113.
8. Guo W, Kong E, Meydani M. Dietary polyphenols, inflammation, and cancer. Nutr Cancer 2009;61:807-810.
9. Korkina LG, De Luca C, Kostyuk VA, Pastore S. Plant polyphenols and tumors: From mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr Med Chem 2009;16:3943-3965.
10. Zhao B. Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem Res 2009;34:630-638.
11. Joseph J, Cole G, Head E, Ingram D. Nutrition, brain aging, and neurodegeneration. J Neurosci 2009;29:12795-12801.
12. Gutierrez-Merino C, Lopez-Sanchez C, Lagoa R, Samhan-Arias AK, Bueno C, Garcia-Martinez V. Neuroprotective actions of flavonoids. Curr Med Chem 2011;18:1195-1212.
13. Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, Ferri C. Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des 2009;15:1072-1084.
14. Michalska M, Gluba A, Mikhailidis DP, Nowak P, Bielecka-Dabrowa A, Rysz J, Banach M. The role of polyphenols in cardiovascular disease. Med Sci Monit 2010;16:RA110-RA119.
15. Agouni A, Lagrue-Lak-Hal AH, Mostefai HA, Tesse A, Mulder P, Rouet P, Desmoulin F, et al. Red wine polyphenols prevent metabolic and cardiovascular alterations associated with obesity in Zucker fatty rats (Fa/Fa). PLoS ONE 2009;4:e5557.
16. Cherniack EP. Polyphenols: Planting the seeds of treatment for the metabolic syndrome. Nutrition 2011;27:617-623.
17. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712-716. (Pubitemid 350207685)
18. Zunino S. Type 2 diabetes and glycemic response to grapes or grape products. J Nutr 2009;139:1794S-1800S.
19. Borriello A, Cucciolla V, Della Ragione F, Galletti P. Dietary polyphenols: Focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutr Metab Cardiovasc Dis 2010;20:618-625.
20. Ferrari CK. Functional foods, herbs and nutraceuticals: Towards biochemical mechanisms of healthy aging. Biogerontology 2004;5:275-289. (Pubitemid 41449156)
21. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8:157-168.
22. Queen BL, Tollefsbol TO. Polyphenols and aging. Curr Aging Sci 2010;3:34-42.
23. Kostyuk V, Potapovich A, De Luca C. The promise of plant polyphenols as the golden standard skin anti-inflammatory agents. Curr Drug Metab 2010;11:414-424.
24. Rahman I, Chung S. Dietary polyphenols, deacetylases and chromatin remodeling in inflammation. World Rev Nutr Diet 2010;101:84-94.
25. Accomando S, Pellitteri V, Corsello G. Natural polyphenols as antiinflammatory agents. Front Biosci (Schol Ed) 2010;2:318-331.
26. Dashwood RH. Frontiers in polyphenols and cancer prevention. J Nutr 2007;137:267S-269S. (Pubitemid 46052891)
27. Ocana A, Tannock IF. When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst 2011;103:16-20.
28. xxxx. Cancer drugs: Remedy required. Nat Med 2011;17:231.
29. Lambert JD, Hong J, Yang GY, Liao J, Yang CS. Inhibition of carcinogenesis by polyphenols: Evidence from laboratory investigations. Am J Clin Nutr 2005;81:284S-291S.
30. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-1421.
31. Kang NJ, Shin SH, Lee HJ, Lee KW. Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol Ther 2011;130:310-324.
32. D'Incalci M, Steward WP, Gescher AJ. Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol 2005;6:899-904. (Pubitemid 41614802)
33. Kandaswami C, Kanadaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT. The antitumor activities of flavonoids. In Vivo 2005;19:895-909.
34. Bracke ME, Vanhoecke BW, Derycke L, Bolca S, Possemiers S, Heyerick A, Stevens CV, et al. Plant polyphenolics as anti-invasive cancer agents. Anticancer Agents Med Chem 2008;8:171-185. (Pubitemid 351761442)
35. Sliva D. Suppression of cancer invasiveness by dietary compounds. Mini Rev Med Chem 2008;8:677-688.
36. Jiang YL, Liu ZP. Natural products as anti-invasive and antimetastatic agents. Curr Med Chem 2011;18:808-829.
37. Ramos S. Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. Mol Nutr Food Res 2008;52:507-526.
38. Granci V, Dupertuis YM, Pichard C. Angiogenesis as a potential target of pharmaconutrients in cancer therapy. Curr Opin Clin Nutr Metab Care 2010;13:417-422.
39. Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal 2005;7:1630-1647. (Pubitemid 41767998)
40. Kroon PA, Clifford MN, Crozier A, Day AJ, Donovan JL, Manach C, Williamson G. How should we assess the effects of exposure to dietary polyphenols in vitro? Am J Clin Nutr 2004;80:15-21. (Pubitemid 41115549)
41. Silberberg M, Morand C, Mathevon T, Besson C, Manach C, Scalbert A, Remesy C. The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur J Nutr 2006;45:88-96. (Pubitemid 43345201)
42. Maier-Salamon A, Hagenauer B, Reznicek G, Szekeres T, Thalhammer T, Jäger W. Metabolism and disposition of resveratrol in the isolated perfused rat liver: Role of Mrp2 in the biliary excretion of glucuronides. J Pharm Sci 2008;97:1615-1628.
43. Murota K, Terao J. Antioxidative flavonoid quercetin: Implication of its intestinal absorption and metabolism. Arch Biochem Biophys 2003;417:12-17. (Pubitemid 36960043)
44. Piskula MK. Factors affecting flavonoids absorption. Biofactors 2000;12:175-180. (Pubitemid 32107404)
45. Lambert JD, Yang CS. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res 2003;523-524:201-208. (Pubitemid 36293247)
46. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 2005;28:823-828.
47. Gao S, Hu M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem 2010;10:550-567.
48. Landis-Piwowar KR, Dou QP. Polyphenols: Biological activities, molecular targets, and the effect of methylation. Curr Mol Pharmacol 2008;1:233-243.
49. Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E, Varea MT, et al. Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 2005;7:37-47. (Pubitemid 40209469)
50. Landis-Piwowar KR, Wan SB, Wiegand RA, Kuhn DJ, Chan TH, Dou QP. Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. J Cell Physiol 2007;213:252-260. (Pubitemid 47378814)
51. Wu B, Kulkarni K, Basu S, Zhang S, Hu M. First-pass metabolism via UDP-glucuronosyltransferase: A barrier to oral bioavailability of phenolics. J Pharm Sci 2011;100:3655-3681.
52. Day AJ, Bao Y, Morgan MR, Williamson G. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic Biol Med 2000;29:1234-1243.
53. Lu H, Meng X, Li C, Sang S, Patten C, Sheng S, Hong J, et al. Glucuronides of tea catechins: Enzymology of biosynthesis and biological activities. Drug Metab Dispos 2003;31:452-461. (Pubitemid 36378523)
54. Liu Z, Hu M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 2007;3:389-406. (Pubitemid 47316031)
55. van de Wetering K, Burkon A, Feddema W, Bot A, de Jonge H, Somoza V, et al. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 2009;75:876-885.
56. Zhang L, Zuo Z, Lin G. Intestinal and hepatic glucuronidation of flavonoids. Mol Pharm 2007;4:833-845.
57. Vaidyanathan JB, Walle T. Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes. Drug Metab Dispos 2002;30:897-903. (Pubitemid 34815419)
58. Wu B, Kulkarni K, Basu S, Zhang S, Hu M. First-pass metabolism via UDP-glucuronosyltransferase: A barrier to oral bioavailability of phenolics. J Pharm Sci 2011;100:3655-3681.
59. Alvarez AI, Real R, Pérez M, Mendoza G, Prieto JG, Merino G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2010;99:598-617.
60. Pérez-Jiménez J, Hubert J, Hooper L, Cassidy A, Manach C, Williamson G, Scalbert A. Urinary metabolites as biomarkers of polyphenol intake in humans: A systematic review. Am J Clin Nutr 2010;92:801-809.
61. Fraga CG, Galleano M, Verstraeten SV, Oteiza PI. Basic biochemical mechanisms behind the health benefits of polyphenols. Mol Aspects Med 2010;31:435-445.
62. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 2003;278:22644-22649. (Pubitemid 36830322)
63. Wong CC, Botting NP, Orfila C, Al-Maharik N, Williamson G. Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6). Biochem Pharmacol 2011;81:942-949.
64. Asensi M, Medina I, Ortega A, Carretero J, Baño MC, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002;33:387-398. (Pubitemid 34786278)
65. Juan ME, Maijó M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 2010;51:391-398.
66. Walle T. Bioavailability of resveratrol. Ann NY Acad Sci 2011; 1215:9-15.
67. Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005;49:482-494. (Pubitemid 40780395)
68. Burkon A, Somoza V. Quantification of free and proteinbound trans-resveratrol metabolites and identification of trans-resveratrol-C/O- conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008;52:549-557.
69. Learmonth DA. A concise synthesis of the 3-O-beta-D-and 4′-Obeta-D-glucuronide conjugates of trans-resveratrol. Bioconjug Chem 2003;14:262-267. (Pubitemid 36169041)
70. Miksits M, Wlcek K, Svoboda M, Kunert O, Haslinger E, Thalhammer T, Szekeres T, Jäger W. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med 2009;75:1227-1230.
71. Hoshino J, Park EJ, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, et al. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 2010;53:5033-5043.
72. Kondratyuk TP, Park EJ, Marler LE, Ahn S, Yuan Y, Choi Y, Yu R, et al. Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol Nutr Food Res 2011;55:1249-1265.
73. Walle T. Absorption and metabolism of flavonoids. Free Radic Biol Med 2004;36:829-837. (Pubitemid 38401062)
74. Manach C, Morand C, Crespy V, Demigné C, Texier O, Régérat F, Rémésy C. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 1998;426:331-336. (Pubitemid 28218374)
75. Morand C, Crespy V, Manach C, Besson C, Demigné C, Rémésy C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol 1998;275:R212-R219.
76. Yamamoto N, Moon JH, Tsushida T, Nagao A, Terao J. Inhibitory effect of quercetin metabolites and their related derivatives on copper ion-induced lipid peroxidation in human low-density lipoprotein. Arch Biochem Biophys 1999;372:347-354. (Pubitemid 30026786)
77. Miyake Y, Shimoi K, Kumazawa S, Yamamoto K, Kinae N, Osawa T. Identification and antioxidant activity of flavonoid metabolites in plasma and urine of eriocitrin-treated rats. J Agric Food Chem 2000;48:3217-3224.
78. Moon JH, Tsushida T, Nakahara K, Terao J. Identification of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med 2001;30:1274-1285. (Pubitemid 32463938)
79. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001;41:492-499. (Pubitemid 32381866)
80. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999;27:486-494.
81. Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 2000;67:2785-2793.
82. Pan MH, Lin-Shiau SY, Lin JK. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 2000;60:1665-1676.
83. Murugan P, Pari L. Influence of tetrahydrocurcumin on hepatic and renal functional markers and protein levels in experimental type 2 diabetic rats. Basic Clin Pharmacol Toxicol 2007;101:241-245. (Pubitemid 350194802)
84. Osawa T. Nephroprotective and hepatoprotective effects of curcuminoids. Adv Exp Med Biol 2007;595:407-423.
85. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004;90:1011-1015. (Pubitemid 38499692)
86. Kida K, Suzuki M, Matsumoto N, Nanjo F, Hara Y. Identification of biliary metabolites of (-)-epigallocatechin gallate in rats. J Agric Food Chem 2000;48:4151-4155.
87. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002;11:1025-1032. (Pubitemid 35192653)
88. Chen D, Wang CY, Lambert JD, Ai N, Welsh WJ, Yang CS. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: Structure-activity relationship and molecular-modeling studies. Biochem Pharmacol 2005;69:1523-1531. (Pubitemid 40602453)
89. Wang P, Aronson WJ, Huang M, Zhang Y, Lee RP, Heber D, Henning SM. Green tea polyphenols and metabolites in prostatectomy tissue: Implications for cancer prevention. Cancer Prev Res (Phila) 2010;3:985-993.
90. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-1252. (Pubitemid 46984966)
91. Edwards JA, Beck M, Riegger C, Bausch J. Safety of resveratrol with examples for high purity, trans-resveratrol, resVida(?). Ann N Y Acad Sci 2011;1215:131-137.
92. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci 2004;82:614-619. (Pubitemid 39600090)
93. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009;47:2170-2182.
94. Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, Crowell JA, et al. Toxicogenomics of resveratrol in rat liver. Life Sci 2005;76:2299-2314. (Pubitemid 40313418)
95. Aeschbacher HU, Meier H, Ruch E. Nonmutagenicity in vivo of the food flavonol quercetin. Nutr Cancer 1982;4:90-98. (Pubitemid 13114434)
96. Utesch D, Feige K, Dasenbrock J, Broschard TH, Harwood M, Danielewska-Nikiel B, Lines TC. Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res 2008;654:38-44.
97. Okamoto T. Safety of quercetin for clinical application (Review). Int J Mol Med 2005;16:275-278.
98. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45:2179-2205. (Pubitemid 47451573)
99. Gugler R, Leschik M, Dengler HJ. Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 1975;9:229-234.
100. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996;2:659-668. (Pubitemid 26133468)
101. Vicentini FT, Fonseca YM, Pitol DL, Iyomasa MM, Bentley MV, Fonseca MJ. Evaluation of protective effect of a waterin-oil microemulsion incorporating quercetin against UVBinduced damage in hairless mice skin. J Pharm Pharm Sci 2010;13:274-285.
102. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: Review of the gap between basic and clinical applications. Curr Med Chem 2010;17:190-197.
103. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). J Altern Complement Med 2003;9:161-168. (Pubitemid 36297021)
104. Karunagaran D, Rashmi R, Kumar TR. Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets 2005;5:117-129. (Pubitemid 40488598)
105. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10.
106. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett 2007;255:170-181. (Pubitemid 47268637)
107. Krishnaraju AV, Sundararaju D, Sengupta K, Venkateswarlu S, Trimurtulu G. Safety and toxicological evaluation of demethylatedcurcuminoids; a novel standardized curcumin product. Toxicol Mech Methods 2009;19:447-460.
108. Gao Y, Li Z, Sun M, Guo C, Yu A, Xi Y, Cui J, et al. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv 2011;18:131-142.
109. Thangapazham RL, Sharma A, Maheshwari RK. Beneficial role of curcumin in skin diseases. Adv Exp Med Biol 2007;595:343-357.
110. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem 2008;114:127-149. (Pubitemid 351892715)
111. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9:3312-3319. (Pubitemid 37082725)
112. Isbrucker RA, Bausch J, Edwards JA, Wolz E. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: Genotoxicity. Food Chem Toxicol 2006;44:626-635.
113. Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: Dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006;44:636-650.
114. Verschoyle RD, Steward WP, Gescher AJ. Putative cancer chemopreventive agents of dietary origin-how safe are they? Nutr Cancer 2007;59:152-162. (Pubitemid 350230732)
115. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
116. Steeg PS. Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 2006;12:895-904. (Pubitemid 44175140)
117. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990;54:159-211. (Pubitemid 20088338)
118. Mehlen P, Puisieux A. Metastasis: A question of life or death. Nat Rev Cancer 2006;6:449-458.
119. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG. Future directions of nextgeneration novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011;29:1916-1923.
120. Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science 2006;312:1171-1175. (Pubitemid 43801134)
121. Sawyers CL. Cancer: Mixing cocktails. Nature 2007;449:993-996. (Pubitemid 350014587)
122. Ortega A, Mena S, Estrela JM. Oxidative and nitrosative stress in the metastatic microenvironment. Cancers 2010;2:274-304.
123. Shackleton M, Quintana E. Progress in understanding melanoma propagation. Mol Oncol 2010;4:451-457.
124. Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005;327:866-870. (Pubitemid 40092828)
125. Fulda S, Debatin KM. Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review. Cancer Detect Prev 2006;30:217-223. (Pubitemid 44163050)
126. Wesolowska O, Wisniewski J, Bielawska-Pohl A, Paprocka M, Duarte N, Ferreira MJ, Dus D, Michalak K. Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells. Anticancer Res 2010;30:4587-4593.
127. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011;1215:150-160.
128. Kim EJ, Choi CH, Park JY, Kang SK, Kim YK. Underlying mechanism of quercetin-induced cell death in human glioma cells. Neurochem Res 2008;33:971-979.
129. Galluzzo P, Martini C, Bulzomi P, Leone S, Bolli A, Pallottini V, Marino M. Quercetin-induced apoptotic cascade in cancer cells: Antioxidant versus estrogen receptor alpha-dependent mechanisms. Mol Nutr Food Res 2009;53:699-708.
130. Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010;15:857-870.
131. Chen C, Zhou J, Ji C. Quercetin: A potential drug to reverse multidrug resistance. Life Sci 2010;87:333-338.
132. Thangasamy T, Sittadjody S, Mitchell GC, Mendoza EE, Radhakrishnan VM, Limesand KH, Burd R. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer 2010;10:282.
133. Bush JA, Cheung KJ Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001;271:305-314. (Pubitemid 33141212)
134. Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B, van Zanden JJ, Rietjens IM, et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: The case of curcumin. Chem Res Toxicol 2003;16:1642-1651. (Pubitemid 38049384)
135. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 2004;68:2043-2052. (Pubitemid 39346194)
136. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 2004;4:13.
137. Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006;6:259-270. (Pubitemid 43796643)
138. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: How spicy is it? Mol Nutr Food Res 2008;52:1010-1030.
139. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 2010;343:489-499.
140. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 2002;1542:149-159.
141. Mei Y, Qian F, Wei D, Liu J. Reversal of cancer multidrug resistance by green tea polyphenols. J Pharm Pharmacol 2004;56:1307-1314. (Pubitemid 39369002)
142. Qian F, Wei D, Zhang Q, Yang S. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Biomed Pharmacother 2005;59:64-69. (Pubitemid 40417515)
143. Chen TC, Wang W, Golden EB, Thomas S, Sivakumar W, Hofman FM, Louie SG, Schönthal AH. Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 2011;302:100-108.
144. Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, Barrand MA. Modulatory effects of plant phenols on human multidrugresistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 2005;272:4725-4740. (Pubitemid 41366995)
145. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109:2293-2302. (Pubitemid 46425866)
146. Kweon SH, Song JH, Kim TS. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 2010;395:104-110.
147. Back JH, Rezvani HR, Zhu Y, Guyonnet-Duperat V, Athar M, Ratner D, Kim AL. Cancer cell survival following DNA damagemediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1. J Biol Chem 2011;286:19100-19108.
148. Senthilkumar K, Arunkumar R, Elumalai P, Sharmila G, Gunadharini DN, Banudevi S, Krishnamoorthy G, et al. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct 2011;29:87-95.
149. Prakobwong S, Gupta SC, Kim JH, Sung B, Pinlaor P, Hiraku Y, Wongkham S, et al. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 2011;32:1372-1380.
150. Dou QP. Molecular mechanisms of green tea polyphenols. Nutr Cancer 2009;61:827-835.
151. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895-899. (Pubitemid 38056882)
152. Yang H, Landis-Piwowar KR, Chen D, Milacic V, Dou QP. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci 2008;9:227-239. (Pubitemid 351997839)
153. Delmas D, Solary E, Latruffe N. Resveratrol, a phytochemical inducer of multiple cell death pathways: Apoptosis, autophagy and mitotic catastrophe. Curr Med Chem 2011;18:1100-1121.
154. Morselli E, Mariño G, Bennetzen MV, Eisenberg T, Megalou E, Schroeder S, Cabrera S, et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol 2011;192:615-629.
155. Jagetia GC. Radioprotection and radiosensitization by curcumin. Adv Exp Med Biol 2007;595:301-320.
156. Johnson GE, Ivanov VN, Hei TK. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 2008;13:790-802.
157. Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, Koumenis C. Thioredoxin reductase-1 mediates curcumininduced radiosensitization of squamous carcinoma cells. Cancer Res 2010;70:1941-1950.
158. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Curcumin-altered p53-response genes regulate radiosensitivity in p53-mutant Ewing's sarcoma cells. Anticancer Res 2010;30:4007-4015.
159. Yang YP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH, et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 2011. (In Press).
160. Bronikowska J, Szliszka E, Czuba ZP, Zwolinski D, Szmydki D, Krol W. The combination of TRAIL and isoflavones enhances apoptosis in cancer cells. Molecules 2010;15:2000-2015.
161. Jacquemin G, Shirley S, Micheau O. Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: A promising approach to kill resistant cancer cells? Cell Mol Life Sci 2010;67:3115-3130.
162. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003;2:95-103.
163. Nozawa F, Itami A, Saruc M, Kim M, Standop J, Picha KS, Cowan KH, Pour PM. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth. Pancreas 2004;29:45-52. (Pubitemid 38857266)
164. Delmas D, Rébé C, Micheau O, Athias A, Gambert P, Grazide S, Laurent G, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004;23:8979-8986. (Pubitemid 39657788)
165. Fulda S, Debatin KM. Sensitization for tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004;64:337-346. (Pubitemid 38114116)
166. Fulda S, Debatin KM. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 2005;41:786-798. (Pubitemid 40342561)
167. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007;6:2591-2599. (Pubitemid 47480425)
168. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 2007;304:273-285. (Pubitemid 47456876)
169. Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes TRAIL-resistant xenografts: Molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 2008;7:16.
170. Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008;27:2055-2063. (Pubitemid 351442738)
171. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS ONE 2010;5:e15288.
172. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 2010;5:e15627.
173. Ferrer P, Asensi M, Priego S, Benlloch M, Mena S, Ortega A, Obrador E, et al. Nitric oxide mediates natural polyphenolinduced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma. J Biol Chem 2007;282:2880-2890. (Pubitemid 47086274)
174. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
175. Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009;20 Suppl 6:vi22-29.
176. Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009;20 Suppl 6:vi14-21.
177. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-220. (Pubitemid 127696281)
178. Jensen JD, Wing GJ, Dellavalle RP. Nutrition and melanoma prevention. Clin Dermatol 2010;28:644-649.
179. Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: Anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 2010;302:71-83.
180. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995;95:221-225.
181. Yan C, Han R. Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein. Invasion Metastasis 1997;17:189-198. (Pubitemid 28495384)
182. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, Aiello FB, Piantelli M. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 2000;87:595-600. (Pubitemid 30639822)
183. Liu JD, Chen SH, Lin CL, Tsai SH, Liang YC. Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. J Cell Biochem 2001;83:631-642.
184. Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL, Rankin GO. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 2006;136:2542-2546. (Pubitemid 44521610)
185. Martínez Conesa C, Vicente Ortega V, Yáñez Gascón MJ, Alcaraz Baños M, Canteras Jordana M, Benavente-García O, Castillo J. Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmin. J Agric Food Chem 2005;53:6791-6797. (Pubitemid 41260725)
186. Guruvayoorappan C, Kuttan G. Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol Immunotoxicol 2008;30:711-727.
187. Nihal M, Ahsan H, Siddiqui IA, Mukhtar H, Ahmad N, Wood GS. (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle 2009;8:2057-2063.
188. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011;10:411-412.
189. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-599.
190. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: From improved survival to potential cure. Oncology 2010;78:237-248.
191. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: A critical appraisal of challenging issues. Arch Pathol Lab Med 2010;134:837-852.
192. Yamane T, Hagiwara N, Tateishi M, Akachi S, Kim M, Okuzumi J, Kitao Y, et al. Inhibition of azoxymethane-induced colon carcinogenesis in rat by green tea polyphenol fraction. Jpn J Cancer Res 1991;82:1336-1339.
193. Narisawa T, Fukaura Y. A very low dose of green tea polyphenols in drinking water prevents N-methyl-N-nitrosoureainduced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1993;84:1007-1009. (Pubitemid 23307832)
194. Shankar S, Ganapathy S, Srivastava RK. Green tea polyphenols: Biology and therapeutic implications in cancer. Front Biosci 2007;12:4881-4899.
195. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274-283. (Pubitemid 47575677)
196. Rudolf E, Andelová H, Cervinka M. Polyphenolic compounds in chemoprevention of colon cancer-targets and signaling pathways. Anticancer Agents Med Chem 2007;7:559-575. (Pubitemid 351836127)
197. Pan MH, Lai CS, Wu JC, Ho CT. Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds. Mol Nutr Food Res 2011;55:32-45.
198. Giavazzi R, Garofalo A, Damia G, Garattini S, D'Incalci M. Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. Br J Cancer 1988;57:277-280. (Pubitemid 18096334)
199. Yuan JH, Li YQ, Yang XY. Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice. Pharmacology 2007;80:269-278.
200. Ogasawara M, Matsunaga T, Suzuki H. Differential effects of antioxidants on the in vitro invasion, growth and lung metastasis of murine colon cancer cells. Biol Pharm Bull 2007;30:200-204. (Pubitemid 46066348)
201. Paul S, Mizuno CS, Lee HJ, Zheng X, Chajkowisk S, Rimoldi JM, Conney A, et al. In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer. Eur J Med Chem 2010;45:3702-3708.
202. Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, Sarkar FH, Majumdar AP. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer 2011;128:951-961.
203. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Kuzhuvelil HB, Deorukhkar A, Gelovani J, et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009;125:2187-2197.
204. Priego S, Feddi F, Ferrer P, Mena S, Benlloch M, Ortega A, Carretero J, et al. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: A Bcl-2-and superoxide dismutase 2-dependent mechanism. Mol Cancer Ther 2008;7:3330-3342.
205. Ruiz MJ, Fernández M, Picó Y, Mañes J, Asensi M, Carda C, Asensio G, Estrela JM. Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J Agric Food Chem 2009;57:3180-3186.
206. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-1380.
207. Finlay GJ, Smith GP, Fray LM, Baguley BC. Effect of flavone acetic acid on Lewis lung carcinoma: Evidence for an indirect effect. J Natl Cancer Inst 1988;80:241-245.
208. Pratesi G, Manzotti C, Tortoreto M, Audisio RA, Zunino F. Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft. Br J Cancer 1991;63:71-74.
209. Katiyar SK, Agarwal R, Mukhtar H. Protective effects of green tea polyphenols administered by oral intubation against chemical carcinogen-induced forestomach and pulmonary neoplasia in A/J mice. Cancer Lett 1993;73:167-172. (Pubitemid 23322296)
210. Komori A, Yatsunami J, Okabe S, Abe S, Hara K, Suganuma M, Kim SJ, Fujiki H. Anticarcinogenic activity of green tea polyphenols. Jpn J Clin Oncol 1993;23:186-190.
211. Sazuka M, Murakami S, Isemura M, Satoh K, Nukiwa T. Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. Cancer Lett 1995;98:27-31.
212. Yang G, Wang ZY, Kim S, Liao J, Seril DN, Chen X, Smith TJ, Yang CS. Characterization of early pulmonary hyperproliferation and tumor progression and their inhibition by black tea in a 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-induced lung tumorigenesis model with A/J mice. Cancer Res 1997;57:1889-1894. (Pubitemid 27209717)
213. Yang CS, Yang GY, Landau JM, Kim S, Liao J. Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression. Exp Lung Res 1998;24:629-639. (Pubitemid 28308956)
214. Wietrzyk J, Boratynski J, Grynkiewicz G, Ryczynski A, Radzikowski C, Opolski A. Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide. Anticancer Res 2001;21:3893-3896. (Pubitemid 34229259)
215. Kim JC, Saha D, Cao Q, Choy H. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 2004;71:213-221. (Pubitemid 38521191)
216. Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 2004;10:8641-8647. (Pubitemid 40053432)
217. Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, Du XB, et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res 2006;12:3193-3199.
218. Hung H. Dietary quercetin inhibits proliferation of lung carcinoma cells. Forum Nutr 2007;60:146-157.
219. Lu G, Xiao H, You H, Lin Y, Jin H, Snagaski B, Yang CS. Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin Cancer Res 2008;14:4981-4988.
220. Cui Y, Morgenstern H, Greenland S, Tashkin DP, Mao JT, Cai L, Cozen W, et al. Dietary flavonoid intake and lung cancer-a population-based case-control study. Cancer 2008;112:2241-2248. (Pubitemid 351628635)
221. Du G, Jin L, Han X, Song Z, Zhang H, Liang W. Naringenin: A potential immunomodulator for inhibiting lung fibrosis and metastasis. Cancer Res 2009;69:3205-3212.
222. Saha A, Kuzuhara T, Echigo N, Suganuma M, Fujiki H. New role of (-)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin. Cancer Prev Res (Phila) 2010;3:953-962.
223. Amin AR, Wang D, Zhang H, Peng S, Shin HJ, Brandes JC, Tighiouart M, et al. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: Potential role of p53. J Biol Chem 2010;285:34557-34565.
224. Shoji Y, Nakashima H. Nutraceutics and delivery systems. J Drug Target 2004;12:385-391. (Pubitemid 39294836)
225. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila) 2009;2:514-517.
226. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001;276:22586-22594.
227. Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke SO. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 2002;50:3453-3457. (Pubitemid 34580577)
228. Coimbra M, Isacchi B, van Bloois L, Torano JS, Ket A, Wu X, Broere F, et al. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm 2011;416:433-442.
229. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 2011;4:1158-1171.
230. Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaffaut L, Mennen L, Knox C, et al. Phenol-Explorer: An online comprehensive database on polyphenol contents in foods. Database (Oxford) 2010;2010:bap024.
231. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279:51163-51171. (Pubitemid 40017859)
232. Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, Bondada S. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol 2007;178:111-121. (Pubitemid 46033592)
233. Han SS, Keum YS, Seo HJ, Surh YJ. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol 2002;35:337-342.
234. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acidand phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999;20:445-451. (Pubitemid 29112633)
235. Kim HI, Huang H, Cheepala S, Huang S, Chung J. Curcumin inhibition of integrin (alpha6beta4)-dependent breast cancer cell motility and invasion. Cancer Prev Res (Phila) 2008;1:385-391.
236. He Z, Tang F, Ermakova S, Li M, Zhao Q, Cho YY, Ma WY, et al. Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol Carcinog 2008;47: 172-183. (Pubitemid 351409338)
237. Li M, He Z, Ermakova S, Zheng D, Tang F, Cho YY, Zhu F, et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 2007;16: 598-605. (Pubitemid 46548666)
238. Larsen CA, Dashwood RH, Bisson WH. Tea catechins as inhibitors of receptor tyrosine kinases: Mechanistic insights and human relevance. Pharmacol Res 2010;62:457-464.
239. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011;25: 1198-1207.
240. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3- gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 2004;279:12755-12762. (Pubitemid 38445847)
241. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, Bowden GT, et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 2008;68:946-955. (Pubitemid 351206774)
242. Hwang MK, Song NR, Kang NJ, Lee KW, Lee HJ. Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: Its direct inhibition by quercetin. Int J Biochem Cell Biol 2009;41:1592-1600.
243. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Rémésy C, Chap H, Payrastre B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 1997;53:1649-1657. (Pubitemid 27356094)
244. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, Bode AM, Dong Z. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 2008;47:797-805.
245. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL Jr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther 2005;4:1923-1935. (Pubitemid 43056975)
246. Yoon SH, Kim YS, Ghim SY, Song BH, Bae YS. Inhibition of protein kinase CKII activity by resveratrol, a natural compound in red wine and grapes. Life Sci 2002;71:2145-2152.